Stay in touch
We'd love to keep in touch about news, events and how you can get involved. To hear from us, please sign up below.
Scientists, based at the Queen Mary University of London, have discovered a new mechanism that signals which Ductal Carcinoma in Situ (DCIS) tumours may progress to invasive breast cancer. This might help avoid unnecessary treatment for some women with DCIS in the future.
PARP inhibitors like olaparib are an exciting new avenue of targeted treatment for breast cancer patients with changes to the BRCA genes. Let’s look at the journey of olaparib from first experiments in the lab until now.
Researchers have discovered weaknesses in some triple negative breast cancers that could lead to new ways to treat this form of the disease.
To celebrate our research successes of the past year our research communications officer, Edd, picked out his favourite discoveries and explains why they are so important.
Researchers have identified a group of immune cells that could be targeted to develop new treatments for breast cancers that are resistant to chemotherapy.
Researchers looked at additional support that could help women discuss their goals and priorities for breast reconstruction surgery with their surgeon.
Researchers have found that an extra radiotherapy boost could reduce the chances of higher risk DCIS coming back in the same breast.
This year we’re celebrating 10 years of the Breast Cancer Now Tissue Bank. By collecting tissue samples from people affected by breast cancer and making them available to researchers, our Tissue Bank accelerates progress towards faster diagnosis and better treatments.
Professor Valerie Speirs is co-principal investigator of the Breast Cancer Now Tissue Bank. Here Valerie and Edward Jones, our research communications officer, discuss how the Bank has grown over the past 10 years to become a phenomenal medical resource.